Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1941471
PUBLISHER: Grand View Research | PRODUCT CODE: 1941471
Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type, By Application, By Administration, By Region, And Segment Forecasts, 2026 - 2033
PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Vaccine Adjuvants Market Summary
The global vaccine adjuvants market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 5.60% from 2026 to 2033. The growth of the market is driven by the increasing demand for effective vaccines to combat emerging and re-emerging infectious diseases, as well as the rising prevalence of chronic conditions such as cancer.
The growing recognition of adjuvants' role in enhancing the efficacy, durability, and breadth of immune responses is propelling their adoption across both prophylactic and therapeutic vaccines. Advancements in immunology and molecular biology have enabled the development of next-generation adjuvants, including saponin-based adjuvants and toll-like receptor (TLR) agonists, which selectively target immune pathways and deliver improved safety and efficacy profiles. These innovations address the unmet need for vaccines capable of eliciting strong immune responses with reduced antigen doses, improving cost efficiency and scalability. For instance, in August 2025, Springer Nature published a review in Medicinal Chemistry Research (Volume 34, pages 1817-1832) highlighting that the widely studied saponin adjuvant QS-21 consists of approximately 65 percent QS-21-Api and 35 percent QS-21-Xyl isomers and has been incorporated into licensed vaccines such as Shingrix, Mosquirix, and Arexvy, with the authors reporting successful biosynthetic elucidation and comparing semi-synthetic yields, including engineered yeast production at roughly 0.0012 percent weight-by-weight versus about 0.0032 percent from natural sources, underscoring its role in enhancing antigen-specific antibody and cellular immune responses.
In addition, rising investments in vaccine research and development by governments, non-governmental organizations, and pharmaceutical companies are accelerating market growth. Global initiatives are playing a central role in expanding access to advanced adjuvanted vaccines, particularly in low- and middle-income countries. For instance, in June 2024, Gavi, the Vaccine Alliance approved its new five-year strategy, Gavi 6.0, committing to support countries in vaccinating more than 500 million additional children and adolescents, projecting the prevention of 8-9 million deaths, including 1.5 million through HPV vaccination, and expanding access to vaccines targeting 20+ diseases during the 2026-2030 period, with an added focus on climate-sensitive diseases such as dengue and the anticipated rollout of a new tuberculosis vaccine by the end of the strategy cycle. These initiatives, alongside heightened pandemic preparedness following COVID-19 and other outbreaks, have reinforced the need for adjuvant-enhanced vaccines that enable rapid development and deployment.
The market also benefits from favorable regulatory support, including expedited approval pathways and targeted funding for critical vaccine technologies. However, challenges such as high development costs, stringent regulatory requirements, and the need for extensive clinical validation remain key barriers. Despite these constraints, the expanding pipeline of adjuvant-based vaccines and growing global awareness of immunization's role in public health continue to position the vaccine adjuvants industry for sustained growth over the forecast period.
Global Vaccine Adjuvants Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine adjuvants market report based on type, application, administration, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Pathogen
- Adjuvant emulsion
- Particulate
- Combination
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Infectious diseases
- Cancer
- Others
- Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Intradermal
- Intranasal
- Intramuscular
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Product Code: GVR-1-68038-612-7
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Application
- 1.1.3. Administration
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. Administration outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Vaccine Adjuvants Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
- 3.4.1. Industry Analysis - Porter's
Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis
- 4.1. Vaccine Adjuvants Market: Key Takeaways
- 4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 4.3. Pathogen
- 4.3.1. Pathogen market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4. Adjuvant emulsion
- 4.4.1. Adjuvant emulsion market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5. Particulate
- 4.5.1. Particulate market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6. Combination
- 4.6.1. Combination market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis
- 5.1. Vaccine Adjuvants Market: Key Takeaways
- 5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 5.3. Infectious diseases
- 5.3.1. Infectious diseases market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4. Cancer
- 5.4.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis
- 6.1. Vaccine Adjuvants Market: Key Takeaways
- 6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 6.3. Oral
- 6.3.1. Oral market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.4. Intradermal
- 6.4.1. Intradermal market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.5. Intranasal
- 6.5.1. Intranasal market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6. Intramuscular
- 6.6.1. Intramuscular market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Vaccine Adjuvants Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.1. UK
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.1. Japan
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.6.1. Brazil
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.1. South Africa
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. GlaxoSmithKline plc
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Novartis/CSL Limited
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Agenus Inc
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Adjuvance Technologies, Inc
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Novavax Inc.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. SPI Pharma
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Invivogen
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Avanti Polar Lipids
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Brentagg
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.1. GlaxoSmithKline plc
Product Code: GVR-1-68038-612-7
List of Tables
- Table 1 List of Abbreviation
- Table 2 North America Vaccine Adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 3 North America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 4 North America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 5 North America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
- Table 6 U.S. vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 7 U.S. vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 8 U.S. vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 9 Canada vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 10 Canada vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 11 Canada vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 12 Mexico vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 13 Mexico vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 14 Mexico vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 15 Europe vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 16 Europe vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 17 Europe vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 18 Europe vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
- Table 19 Germany vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 20 Germany vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 21 Germany vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 22 UK vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 23 UK vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 24 UK vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 25 France vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 26 France vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 27 France vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 28 Italy vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 29 Italy vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 30 Italy vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 31 Spain vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 32 Spain vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 33 Spain vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 34 Denmark vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 35 Denmark vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 36 Denmark vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 37 Sweden vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 38 Sweden vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 39 Sweden vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 40 Norway vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 41 Norway vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 42 Norway vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 43 Asia Pacific vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 44 Asia Pacific vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 45 Asia Pacific vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 46 Asia Pacific vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
- Table 47 Japan vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 48 Japan vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 49 Japan vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 50 China vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 51 China vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 52 China vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 53 India vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 54 India vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 55 India vaccine adjuvants market, by administration, (USD Million) 2021 - 2033
- Table 56 Australia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 57 Australia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 58 Australia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 59 Thailand vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 60 Thailand vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 61 Thailand vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 62 South Korea vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 63 South Korea vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 64 South Korea vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 65 Latin America vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 66 Latin America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 67 Latin America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 68 Latin America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
- Table 69 Brazil vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 70 Brazil vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 71 Brazil vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 72 Argentina vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 73 Argentina vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 74 Argentina vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 75 Middle East and Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 76 Middle East and Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 77 Middle East and Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 78 Middle East and Africa vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
- Table 79 South Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 80 South Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 81 South Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 82 Saudi Arabia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 83 Saudi Arabia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 84 Saudi Arabia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 85 UAE vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 86 UAE vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 87 UAE vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
- Table 88 Kuwait vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
- Table 89 Kuwait vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
- Table 90 Kuwait vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 QFD modeling for market share assessment
- Fig. 6 Market formulation & validation
- Fig. 7 Vaccine adjuvants: Market outlook
- Fig. 8 Vaccine adjuvants: Competitive insights
- Fig. 9 Parent market outlook
- Fig. 10 Related/ancillary market outlook
- Fig. 11 Penetration and growth prospect mapping
- Fig. 12 Industry value chain analysis
- Fig. 13 Vaccine adjuvants market driver impact
- Fig. 14 Vaccine adjuvants market restraint impact
- Fig. 15 Vaccine adjuvants market strategic initiatives analysis
- Fig. 16 Vaccine adjuvants market: Type movement analysis
- Fig. 17 Vaccine adjuvants market: Type outlook and key takeaways
- Fig. 18 Pathogen market estimates and forecasts, 2021 - 2033
- Fig. 19 Adjuvant emulsion market estimates and forecasts, 2021 - 2033
- Fig. 20 Particulate market estimates and forecasts, 2021 - 2033
- Fig. 21 Combination market estimates and forecasts, 2021 - 2033
- Fig. 22 Others market estimates and forecasts, 2021 - 2033
- Fig. 23 Vaccine adjuvants market: Application movement analysis
- Fig. 24 Vaccine adjuvants market: Application outlook and key takeaways
- Fig. 25 Infectious diseases market estimates and forecasts, 2021 - 2033
- Fig. 26 Cancer market estimates and forecasts, 2021 - 2033
- Fig. 27 Others market estimates and forecasts, 2021 - 2033
- Fig. 28 Vaccine adjuvants market: Administration movement analysis
- Fig. 29 Vaccine adjuvants market: Administration outlook and key takeaways
- Fig. 30 Oral market estimates and forecasts, 2021 - 2033
- Fig. 31 Intradermal market estimates and forecasts, 2021 - 2033
- Fig. 32 Intranasal market estimates and forecasts, 2021 - 2033
- Fig. 33 Intramuscular market estimates and forecasts, 2021 - 2033
- Fig. 34 Others market estimates and forecasts, 2021 - 2033
- Fig. 35 Global vaccine adjuvants market: Regional movement analysis
- Fig. 36 Global vaccine adjuvants market: Regional outlook and key takeaways
- Fig. 37 North America market estimates and forecasts, 2021 - 2033
- Fig. 38 U.S. market estimates and forecasts, 2021 - 2033
- Fig. 39 Canada market estimates and forecasts, 2021 - 2033
- Fig. 40 Mexico market estimates and forecasts, 2021 - 2033
- Fig. 41 Europe. market estimates and forecasts, 2021 - 2033
- Fig. 42 UK market estimates and forecasts, 2021 - 2033
- Fig. 43 Germany market estimates and forecasts, 2021 - 2033
- Fig. 44 France market estimates and forecasts, 2021 - 2033
- Fig. 45 Italy market estimates and forecasts, 2021 - 2033
- Fig. 46 Spain market estimates and forecasts, 2021 - 2033
- Fig. 47 Denmark market estimates and forecasts, 2021 - 2033
- Fig. 48 Sweden market estimates and forecasts, 2021 - 2033
- Fig. 49 Norway market estimates and forecasts, 2021 - 2033
- Fig. 50 Asia Pacific market estimates and forecasts, 2021 - 2033
- Fig. 51 Japan market estimates and forecasts, 2021 - 2033
- Fig. 52 China market estimates and forecasts, 2021 - 2033
- Fig. 53 India market estimates and forecasts, 2021 - 2033
- Fig. 54 Australia market estimates and forecasts, 2021 - 2033
- Fig. 55 Thailand market estimates and forecasts, 2021 - 2033
- Fig. 56 South Korea market estimates and forecasts, 2021 - 2033
- Fig. 57 Latin America market estimates and forecasts, 2021 - 2033
- Fig. 58 Brazil market estimates and forecasts, 2021 - 2033
- Fig. 59 Argentina market estimates and forecasts, 2021 - 2033
- Fig. 60 Middle East and Africa. market estimates and forecasts, 2021 - 2033
- Fig. 61 South Africa market estimates and forecasts, 2021 - 2033
- Fig. 62 Saudi Arabia market estimates and forecasts, 2021 - 2033
- Fig. 63 UAE market estimates and forecasts, 2021 - 2033
- Fig. 64 Kuwait market estimates and forecasts, 2021 - 2033
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.